Effect of Renin-Angiotensin-Aldosterone System Triple Blockade on Non-Diabetic Renal Disease: Addition of an Aldosterone Blocker, Spironolactone, to Combination Treatment with an Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker (original) (raw)

• Russo D, Pisani A, Balletta MM, et al : Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851–856.
  Article CAS PubMed Google Scholar
• Russo D, Minutolo R, Pisani A, et al : Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18–25.
  Article CAS PubMed Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T : Combination treatment of angiotensin-II receptor blocker and angiotensin-converting−enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117–124.
  Article CAS PubMed Google Scholar
• Okubo S, Niimura F, Nishimura H, et al : Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion. J Clin Invest 1997; 99: 855–860.
  Article CAS PubMed PubMed Central Google Scholar
• Epstein M : Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001; 37: 677–688.
  Article CAS PubMed Google Scholar
• Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B : Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33: 40–45.
  Article CAS PubMed Google Scholar
• Pitt B : “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145–149.
  Article CAS PubMed Google Scholar
• Sato A, Saruta T : Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13–21.
  Article CAS PubMed Google Scholar
• Naruse M, Tanabe A, Sato A, et al : Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28–33.
  Article CAS PubMed Google Scholar
• Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C : Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt−induced fibrosis. Hypertension 1999; 33: 981–986.
  Article CAS PubMed Google Scholar
• Harada E, Yoshimura M, Yasue H, et al : Aldosterone induces angiotensin-converting−enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 2001; 104: 137–139.
  Article CAS PubMed Google Scholar
• Sugiyama T, Yoshimoto T, Tsuchiya K, et al : Aldosterone induces angiotensin converting enzyme gene expression via a JAK2-dependent pathway in rat endothelial cells. Endocrinology 2005; 146: 3900–3906.
  Article CAS PubMed Google Scholar
• Epstein M : Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001; 40: 573–583.
  Article CAS PubMed Google Scholar
• Pitt B, Reichek N, Willenbrock R, et al : Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831–1838.
  Article CAS PubMed Google Scholar
• White WB, Duprez D, St Hillaire R, et al : Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–1026.
  Article CAS PubMed Google Scholar
• Takeda Y : Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res 2004; 27: 781–789.
  Article CAS PubMed Google Scholar
• Chrysostomou A, Becker G : Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345: 925–926.
  Article CAS PubMed Google Scholar
• Bianchi S, Bigazzi R, Campese VM : Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45–51.
  Article CAS PubMed Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, et al : Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829–2836.
  Article CAS PubMed Google Scholar
• Bianchi S, Bigazzi R, Campese VM : Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116–2123.
  Article CAS PubMed Google Scholar
• Schjoedt KJ, Rossing K, Juhl TR, et al : Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536–542.
  Article CAS PubMed Google Scholar
• Chrysostomou A, Pedagogos E, MacGregor L, Becker G : Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or wihtout an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256–262.
  Article CAS PubMed Google Scholar
• Pitt B, Zannad F, Remme WJ, et al, Randomized Aldactone Evaluation Study Investigators : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.
  Article CAS PubMed Google Scholar
• Sato A, Hayashi K, Naruse M, Saruta T : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–68.
  Article CAS PubMed Google Scholar
• Bakris GL, Williams M, Dworkin L, et al : Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646–661.
  Article CAS PubMed Google Scholar
• Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D : The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682–1685.
  Article CAS PubMed Google Scholar
• Shimizu N, Miyashita H, Koide K, Yoshikawa J : Antipressor effect of spironolactone or thyazide diuretics for essential hypertension: double blind comparative study. Horumon To Rinsho 1977; 25: 167–174 ( in Japanese).
  CAS PubMed Google Scholar
• Ginsberg JM, Chang BS, Matarese RA, Garella S : Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309: 1543–1546.
  Article CAS PubMed Google Scholar
• Schwab SJ, Christensen RL, Dougherty K, Klahr S : Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147: 943–944.
  Article CAS PubMed Google Scholar
• Kawasaki T, Ueno M, Uezono K, et al : Average urinary excretion of sodium in 24 hours can be estimated from a spot-urine specimen. Jpn Circ J 1982; 46: 948–953.
  Article CAS PubMed Google Scholar
• Kawamura M, Kusano Y, Takahashi T, Owada M, Sugawara T : Effectiveness of a spot urine method in evaluating daily salt intake in hypertensive patients taking oral antihypertensive drugs. Hypertens Res 2006; 29: 397–402.
  Article CAS PubMed Google Scholar
• Obata K, Iwata K, Ichida T, et al : One step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta 1989; 181: 293–303.
  Article CAS PubMed Google Scholar
• Donovan KL, Coles GA, Williams JD : An ELISA for the detection of type IV collagen in human urine—application to patients with glomerulonephritis. Kidney Int 1994; 46: 1431–1437.
  Article CAS PubMed Google Scholar
• Cameron JS, Blandford G : The simple assessment of selectivity in heavy proteinuria. Lancet 1966; 2: 242–247.
  Article CAS PubMed Google Scholar
• Sato A, Hayashi K, Saruta T : Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44–49.
  Article CAS PubMed Google Scholar
• Han KH, Kang YS, Han SY, et al : Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 2006; 70: 111–120.
  Article CAS PubMed Google Scholar
• Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ : Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002; 87: 448–452.
  Article CAS PubMed Google Scholar
• Brown NJ, Vaughan DE, Fogo AB : The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 2002; 22: 399–406.
  Article CAS PubMed Google Scholar
• Goumenos DS, Tsakas S, El Nahas AM, et al : Transforming growth factor-beta(1) in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 2002; 17: 2145–2152.
  Article CAS PubMed Google Scholar
• Agarwal R, Siva S, Dunn SR, Sharma K : Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002; 39: 486–492.
  Article CAS PubMed Google Scholar
• Sato A, Suzuki Y, Saruta T : Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17–22.
  Article CAS PubMed Google Scholar
• Asai M, Monkawa T, Marumo T, et al : Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. Hypertens Res 2004; 27: 971–978.
  Article CAS PubMed Google Scholar
• Sato A, Saruta T, Funder JW : Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211–216.
  Article CAS PubMed Google Scholar
• McKelvie RS, Yusuf S, Pericak D, et al : Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–1064.
  Article CAS PubMed Google Scholar
• Tang WH, Vagelos RH, Yee YG, et al : Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 70–78.
  Article CAS PubMed Google Scholar
• Price DA, Porter LE, Gordon M, et al : The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999; 10: 2382–2391.
  CAS PubMed Google Scholar
• Hollenberg NK, Price DA, Fisher ND, et al : Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003; 63: 172–178.
  Article CAS PubMed Google Scholar
• Watanabe H, Sanada H, Shigetomi S, Katoh T, Watanabe T : Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron 2000; 86: 27–35.
  Article CAS PubMed Google Scholar
• Okonogi H, Nishimura M, Utsunomiya Y, et al : Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol 2001; 55: 357–364.
  CAS PubMed Google Scholar
• Tomino Y, Suzuki S, Azushima C, et al : Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal 2001; 15: 188–192.
  Article CAS PubMed PubMed Central Google Scholar
• Nishimura M, Sasaki T, Ohishi A, et al : Angiotensin-converting enzyme inhibitors and probucol suppress the time-dependent increase in urinary Type IV collagen excretion of Type II diabetes mellitus patients with early diabetic nephropathy. Clin Nephrol 2001; 56: 96–103.
  CAS PubMed Google Scholar
• Goodfield NE, Newby DE, Ludlam CA, Flapan AD : Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 1999; 99: 2983–2985.
  Article CAS PubMed Google Scholar
• Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A : Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001; 14: 921–926.
  Article CAS PubMed Google Scholar
• Uzu T, Harada T, Namba T, et al : Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005; 23: 861–865.
  Article CAS PubMed Google Scholar
• Sato A, Saruta T : Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303–310.
  Article CAS PubMed Google Scholar
• Pitt B, Williams G, Remme W, et al : The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79–87.
  Article CAS PubMed Google Scholar
• Juurlink DN, Mamdani MM, Lee DS, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–551.
  Article CAS PubMed Google Scholar